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i.org/10.10chronic disease. However, risk prediction in patients admitted with acute decom-
pensated heart failure (ADHF) remains a challenge. ADHF is not a single disease: it
presents in various manners, and different causes may underlie ADHF, which may be
reflected by different biomarkers. Soluble suppression of tumorigenicity 2 (ST2) has
been shown to be a strong independent predictor of short-, mid-, and long-term
outcome in ADHF. Furthermore, combining biomarkers may help further improve
the prognostic power of ST2. The ProBNP Investigation of Dyspnea in the Emer-
gency Department study showed that elevated plasma levels of ST2 together with
elevated levels of 4 other biomarkers have clear incremental values to predict outcome
in ADHF. The Multinational Observational Cohort on Acute Heart Failure study is an
international collaborative network that recruited 5,306 patients hospitalized for
ADHF that demonstrated that ST2 and midregional pro-adrenomedulin had inde-
pendently strong value to predict 30-day and 1-year outcome in patients with ADHF.
The Multinational Observational Cohort on Acute Heart Failure study also showed
that C-reactive protein plus ST2 better classified risk in patients with ADHFs than
ST2 alone. Combining biomarkers for risk prediction or risk stratification might have
clinical and more importantly pathophysiological meaning.  2015 Elsevier Inc. All
rights reserved. (Am J Cardiol 2015;115[suppl]:38Be43B)The use of biomarkers to assist in the care of acute decom-
pensated heart failure (ADHF) patients has been an area of
vastly expanding research.Natriuretic peptides (NPs) represent
the current biomarker gold standard for diagnosis and prog-
nosis in patients with ADHF.1 Subsequent study of the NPs
demonstrates considerable opportunity to add to the prognostic
information gained from their measurement. In this regard,
newer biomarkers have been studied either alone or together
with theNPs. Elevated plasma levels of the interleukin receptor
family member suppression of tumorigenicity 2 (ST2)2
and others, such as midregional pro-adrenomedullin
(MR-proADM), the pro-peptide of a prognostically meaning-
ful endogenous vasoconstrictor,3 have been individually
shown to be associated with poorer outcome in ADHF.iderot, PRES Sorbonne Paris Cité and Saint Louis
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16/j.amjcard.2015.01.039Recently, various studies tested combined biomarkers to pre-
dict outcome in ADHF. Indeed, plasma levels of NPs are more
related to myocardial stress, whereas MR-proADM might be
more related to global stress and ST2 might better reflect
ventricular fibrosis and remodeling. Combining those novel
biomarkers was shown to have additive values.
Clinical Models to Risk Stratify Severe Critically Ill
Patients
Different prognostic systems, such as the Acute Physiology
and Chronic Health Evaluation II or III, the Simplified Acute
Physiology Score (SAPS) II, and the Mortality Probability
Models II, have been developed to predict the outcome of
critically ill patients admitted to the intensive care unit (ICU).
SAPS II provides a method to convert the score to a proba-
bility of hospital mortality4 and includes several key clinical
parameters and biological markers, measured all at admission
and known to alter outcome. Clinical parameters include
age, gender, cause of ICU admission, co-morbidities, blood
pressure, heart rate, and temperature. Several biological
parameters recorded at admission are used to calculate
the SAPS II, including arterial oxygenation, bicarbonates,
liver and renal function markers, and potassium and sodium.
SAPS II score can, however, only be measured at admission
and is not used to follow patient condition. SAPS II has been
shown to be a moderate marker of 28-day outcome.
To follow the severity of patients admitted in the ICU
during their initial hospital stay, an organ dysfunction scorewww.AJConline.org
Figure 1. Mortality rates at 1 year as a function of ST2 and NT-proBNP concentrations. Concentrations of sST2 were measured using an early research-use-
only assay rather than the Presage ST2 method. From Januzzi et al2 with permission.
Figure 2. Cumulative hazard curves demonstrating the ability of a multi-
marker strategy using CRP, ST2, BUN, hemoglobin, and NT-proBNP to
predict hazard both early and in a sustained fashion. From Rehman et al8
with permission. BUN ¼ blood urea nitrogen.
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Assessment (SOFA) score to describe organ dysfunction/
failure.5 The SOFA score is mostly based on biological
markers and has been seen by intensivists as a “multimarker
strategy” to predict outcome. Indeed, in septic patients,
various organ dysfunctions are present at admission, and the
degree and the number of organ dysfunction are associated
with outcome. SOFA score was described to assess the degree
and the number of organ dysfunction at admission and during
the following days. SOFA score is mostly based on biological
markers and includes respiratory, kidney, liver, and coagu-
lation markers. Importantly, none of the aforementioned
scores include measurement of cardiac biomarkers.
Combined Troponin and NPs Use in ADHF
Plasma measurements of troponin and NPs are recommended
in the initial phase of ADHF management. Plasma troponin
levels may help ruling out an acute myocardial infarction as a
main cause of ADHF. Elevated cardiac troponin levels at
Table 1
Risk prediction and reclassification for all-cause one-year mortality in ADHF with a combination of plasma CRP and ST2 at admission to a clinical model
Alive Predicted mortality Clinical þ biomarker (CRPþsST2) model
Low < 20% Intermediate 20 - 60% High > 60% Total
Clinical model Low < 20% 121 15 0 136
Intermediate 20 - 60% 50 111 13 174
High > 60% 0 6 4 10
Total 171 132 17 320
Dead Predicted mortality Clinical þ biomarker (CRPþsST2) model
Low < 20% Intermediate 20 - 60% High > 60% Total
Clinical model Low < 20% 14 5 0 19
Intermediate 20 - 60% 8 73 22 103
High > 60% 0 3 13 16
Total 22 81 35 138
NRI [95%CI]: 20.3[ 9.9-30.7], p-value: <0.001; NRI alive 8.8% ; NRI dead 11.6%.
IDI [95% CI]: 0.08[ 0.05-0.10]; p-value: <0.001.
Comparing the clinical model versus the clinicalþbiomarker (CRPþST2) model, the green cells are patients who changed risk category in a beneficial
direction with addition of biomarkers to the model, while light blue numbers are patients who were reclassified in the inappropriate direction. Patients in the
diagonal boxes (grey) have the same predicted risk with both models. The top table concerns one-year survivors and bottom table one-year non-survivors. From
the top table, the NRI alive is calculated as follows: (56-26)/320 ¼ 0.88 (or 8.8%). From J Lassus et al 12 with permission.
40B The American Journal of Cardiology (www.AJConline.org) Vol 115 (7S) April 2, 2015admission have also been correlated with poor prognosis. It
has further been demonstrated that patients with ADHF with
detectable troponin I and elevated BNP were at particularly
high risk of death, whereas patients with ADHF without
detectable troponin I and lower BNP levels had a substan-
tially lower risk of adverse outcome.6 With the development
and spread of highly sensitive troponin methods, the prog-
nostic impact of troponin measurement has increased.Multimarker Strategy Including ST2 in Patients
Admitted for Acute Dyspnea
Pascual-Figal et al7 prospectively studied 107 patients hos-
pitalized with ADHF (mean age 72 13 years, 44%men, left
ventricular ejection fraction 47  15%). Blood samples were
collected on presentation to measure ST2 (reflective of
myocardial fibrosis and remodeling), high-sensitivity
troponin T (hsTnT—indicative of myocardial necrosis), and
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
(identifying myocardial stretch) levels. Each provided inde-
pendent and additive prognostic information for death in the
shorter and longer term. Furthermore, a simple combined
multimarker score powerfully identified patients at low, in-
termediate, and high risk for all-cause mortality. The presence
of none, 1, 2, or 3 elevated biomarkers was associated with a
strikingly steeply rising incremental risk of death, ranging
from 0% to 50%. The addition of this simple multimarker
score significantly increased the predictive performance
achieved by the entire model taking into account clinical
predictors plus NT-proBNP levels. The survival curves sug-
gest that biomarkers add prognostic information during the
first year and clearly separate those patients at low risk (none
or 1 biomarker elevated) from those at high risk (2 bio-
markers elevated). This simple and objective ability to stratifypatients into very low and very high risk could be used
to triage patients with ADHF to different therapeutic in-
terventions, ranging from low-risk HF observation units to
earlier triage to mechanical support for those at very high risk.
A multimarker strategy has also been evaluated by the
Pro-Betype natriuretic peptide Investigation of Dyspnea in
the Emergency Department (PRIDE) Investigators.2 Of
560 patients from PRIDE, 180 had ADHF. Concentrations
of NT-proBNP, MR-proADM, and MR-proANP were
measured, and patients were followed for 4 years for survival.
In comprehensive statistical analyses, both midregional
peptides were associated with death out to 4 years, individ-
ually or in a multimarker strategy. Figure 1 further shows that
the association of ST2 and NT-proBNP might have additive
values to predict 1-year outcome in patients with both acute
heart failure and more globally acute dyspnea.
Using the same PRIDE database, in addition to ST2 and
NT-proBNP, other plasma markers might have additional
values (87) (Figure 2). Thus, elevated values of ST2,
NT-proBNP, C-reactive protein (CRP), hemoglobin, and
blood urea nitrogen provided independent and incremental
prognostic information. The number of increased biological
markers, assessed simultaneously after admission for acute
dyspnea, provided powerful prognostic information that was
independent and additive to each other.Novel Statistical Methods to Assess an Improved
Performance of Biomarkers
Net reclassification improvement (NRI) has recently gained
attention for examining value of biomarkers in clinical
care. Traditionally, standard prognostic models assessed in-
cremental value of biomarkers by comparing the area under
the curve of the receiver operating characteristic between a
Figure 3. Correlations between ST2 and various cardiovascular biomarkers
in patients with ADHF.
Mebazaa et al/Multimarker in ADHF 41Bclinical model alone versus a clinical model þ biomarkers.
Discrimination (by means of area under the curve or
c-statistic) achieved popularity in diagnostic testing because
sensitivity and specificity test characteristics are relevant
to elucidate diseased versus nondiseased patients. Discrimi-
nation alone was extensively used in pioneer articles on NPs9
and ST2 in patients admitted with acute dyspnea.2 However,
discrimination by itself may not be optimal when comparing
models for risk prediction or to stratify individuals into risk
categories.10
More recently, Pencina et al11 introduced a distinction
between risk “prediction” and risk “classification,” suggest-
ing that measures such as patient reclassification, which goes
beyond statistical significance, and c-statistic are necessary.
Thus, as listed in Table 1, NRI offers a simple intuitive way
of quantifying improvement offered by novel markers on the
top of clinical model. Studies focused on NRI yielded by ST2
demonstrate favorable data in ADHF, with additive value
compared with other biomarkers, for example, the combi-
nation of CRP plus ST2markedly improved risk stratification
in patients with ADHF (Table 1). Such improvement in risk
stratification was seen both in survivors and nonsurvivors of
ADHF.7 Among decedents, the NRI of patients dying was
11.6%. This meant that at least 11.6% of the patients with
ADHF were better classified into higher risk using CRP þ
ST2 on top of the clinical model than the clinical model
alone. Among survivors, the NRI for survivors was 8.8%.Plasma-Soluble ST2 Alone or Combined to Other
Biomarkers for Risk Stratification of PatientsWithADHF
We compared various novel and known prognostic cardio-
vascular biomarkers reflective of different pathobiological
pathways to predict outcome in a large cohort of patients with
ADHF in The Multinational Observational Cohort on Acute
Heart Failure study.12 To explore whether ST2 might be
correlated to other prognostic biomarkers, we first compared
plasma concentration of ST2, NT-proBNP, MR-proADM,
and CRP.12 Figure 3 shows a relatively strong correlation
observed between MR-proADM and ST2 (R ¼ 0.59,
p <0.001), with moderate correlations found between
NT-proBNP and ST2 (R ¼ 0.42, p <0.001). CRP showed
weak associations with ST2.
The Multinational Observational Cohort on Acute Heart
Failure study was designed to equitably assess the individual
and added value of various novel biomarkers (including
ST2) to traditional clinical variables. Figure 4 illustrates
that both ST2 and MR-proADM had striking NRI beyond
clinical variables to predict 30-day mortality. This demon-
strates that if measured at admission, each of the 2 novel
biomarkers markedly improve the risk stratification of pa-
tients with ADHF. Although combination of ST2 with other
biomarkers, such as CRP, did not add much to predict 30-day
Figure 4. Cumulative hazard curves demonstrating the ability of a multimarker strategy using CRP, ST2, BUN, hemoglobin, and NT-proBNP to predict hazard both
early and in a sustained fashion. Horizontal lines represent the NRI of ST2. From J Lassus et al12 with permission. BUN ¼ blood urea nitrogen; CI ¼ confidence
interval.
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Figure 5. Kaplan-Meier of survival rate comparing various CRP þ ST2
levels. CI ¼ confidence interval; HR ¼ hazard ratio; neg. ¼ negative;
pos. ¼ positive.
Mebazaa et al/Multimarker in ADHF 43Bmortality, it had important effect of 1-year mortality. Kaplan-
Meier curves (Figure 5) confirmed a twofold increased risk of
death in patients with ADHF with elevated plasma levels of
ST2 or CRP and fourfold increased risk if both CRP and ST2
were elevated.Future Perspectives and Unanswered Questions
ADHF is a complex cardiovascular disease with alteration of
various organ functions making analysis of clinical and
“classical” biological tests complex to interpret. A better
understanding of the best combination of biomarkers for
evaluating risk in a multimarker strategy is needed.
Furthermore, identifying therapeutic strategies that might
follow recognition of an elevated set of such biomarkers is a
much needed next step.
In conclusion, novel biomarkers, either alone or in com-
bination as multimarker panels, have been shown to markedly
improve and clarify the prognosis of ADHF. Among them,
ST2 emerges as a candidate biomarker to be incorporated in
such panels given its relevant impact in discrimination and
patient reclassification. Future new biomarkers may eventu-
ally provide additive values to risk stratification of patients
with ADHF to optimize management in both the initial phase
at admission and later during the hospital stay.Author Disclosures
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